Is Angi, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Angi, Inc. has moved from very attractive to attractive. Based on the current metrics, Angi appears to be undervalued. The company has a P/E ratio of 16, a price to book value of 0.81, and an EV to EBITDA ratio of 8.45, indicating that it is trading at a discount relative to its earnings and book value.
In comparison to its peers, Angi's P/E ratio of 14.77 is notably lower than GoodRx Holdings, Inc., which has a P/E of 31.76, suggesting that Angi is undervalued relative to this competitor. Additionally, eGain Corp. has a lower P/E of 6.67, but Angi's overall valuation metrics still suggest a more favorable position. While specific return data is not available, the lack of significant returns compared to the S&P 500 reinforces the notion that Angi's current valuation may not fully reflect its potential.